|
1
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baker AH and van Rooij E: miRNA
overexpression induces cardiomyocyte proliferation in vivo. Mol
Ther. 21:497–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heinzelmann J, Henning B, Sanjmyatav J, et
al: Specific miRNA signatures are associated with metastasis and
poor prognosis in clear cell renal cell carcinoma. World J Urol.
29:367–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang JF, Fu WM, He ML, et al: MiRNA-20a
promotes osteogenic differentiation of human mesenchymal stem cells
by co-regulating BMP signaling. RNA Biol. 8:829–838. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ventura A and Jacks T: MicroRNAs and
cancer: short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bosch FX, Ribes J, Díaz M and Cléries R:
Primary liver cancer: worldwide incidence and trends.
Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Giordano S and Columbano A: MicroRNAs: new
tools for diagnosis, prognosis, and therapy in hepatocellular
carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar
|
|
11
|
Augello C, Vaira V, Caruso L, et al:
MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster
as a novel prognostic biomarker in hepatocellular carcinoma. Liver
Int. 32:772–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garofalo M, Di Leva G, Romano G, et al:
miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gramantieri L, Ferracin M, Fornari F, et
al: Cyclin G1 is a target of miR-122a, a microRNA frequently
down-regulated in human hepatocellular carcinoma. Cancer Res.
67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kota J, Chivukula RR, O’Donnell KA, et al:
Therapeutic microRNA delivery suppresses tumorigenesis in a murine
liver cancer model. Cell. 137:1005–1017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu Y, Lu Y, Zhang Q, et al:
MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S
transition by activating the pRb protein. Nucleic Acids Res.
40:4615–4625. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alajez NM, Lenarduzzi M, Ito E, et al:
MiR-218 suppresses nasopharyngeal cancer progression through
downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res.
71:2381–2391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao CP, Zhang Z, Liu W, Xiao S, Gu W and
Lu H: Reduced microRNA-218 expression is associated with high
nuclear factor kappa B activation in gastric cancer. Cancer.
116:41–49. 2010.
|
|
19
|
Li Q, Zhu F and Chen P: miR-7 and miR-218
epigenetically control tumor suppressor genes RASSF1A and Claudin-6
by targeting HoxB3 in breast cancer. Biochem Biophys Res Commun.
424:28–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Y, Yan W, Zhang W, et al: MiR-218
reverses high invasiveness of glioblastoma cells by targeting the
oncogenic transcription factor LEF1. Oncol Rep. 28:1013–1021.
2012.PubMed/NCBI
|
|
21
|
Martinez I, Gardiner AS, Board KF, Monzon
FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces
the expression of microRNA-218 in cervical carcinoma cells.
Oncogene. 27:2575–2582. 2008. View Article : Google Scholar :
|
|
22
|
Uesugi A, Kozaki K, Tsuruta T, et al: The
tumor suppressive microRNA miR-218 targets the mTOR component
rictor and inhibits AKT phosphorylation in oral cancer. Cancer
Research. 71:5765–5778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
White NMA, Bao TT, Grigull J, et al: miRNA
profiling for clear cell renal cell carcinoma: biomarker discovery
and identification of potential controls and consequences of miRNA
dysregulation. J Urol. 186:1077–1083. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu DW, Cheng YW, Wang J, Chen CY and Lee
H: Paxillin predicts survival and relapse in non-small cell lung
cancer by microRNA-218 targeting. Cancer Res. 70:10392–10401. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li C, Tu K, Zheng X, et al: MicroRNA-218
expression and its role in hepatocellular carcinoma. Nan Fang Yi Ke
Da Xue Xue Bao. 33:1127–1131. 2013.In Chinese. PubMed/NCBI
|
|
26
|
Ye W, Yao Q, Zhang M, Wen Q and Wang J:
miR-520a regulates ErbB4 expression and suppresses proliferation
and invasion of esophageal squamous cell carcinoma. Nan Fang Yi Ke
Da Xue Xue Bao. 34:164–168. 2014.In Chinese. PubMed/NCBI
|
|
27
|
Attwooll C, Lazzerini Denchi E and Helin
K: The E2F family: specific functions and overlapping interests.
EMBO J. 23:4709–4716. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dimova DK and Dyson NJ: The E2F
transcriptional network: old acquaintances with new faces.
Oncogene. 24:2810–2826. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren B, Cam H, Takahashi Y, et al: E2F
integrates cell cycle progression with DNA repair, replication, and
G(2)/M checkpoints. Genes Dev. 16:245–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen C and Wells AD: Comparative analysis
of E2F family member oncogenic activity. PLoS ONE. 2:e9122007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Santoni-Rugiu E, Jensen MR and
Thorgeirsson SS: Disruption of the pRb/E2F pathway and inhibition
of apoptosis are major oncogenic events in liver constitutively
expressing c-myc and transforming growth factor alpha. Cancer Res.
58:123–134. 1998.PubMed/NCBI
|
|
32
|
Zhan L, Huang C, Meng XM, et al: Promising
roles of mammalian E2Fs in hepatocellular carcinoma. Cell Signal.
26:1075–1081. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong Q, Meng P, Wang T, et al: MicroRNA
let-7a inhibits proliferation of human prostate cancer cells in
vitro and in vivo by targeting E2F2 and CCND2. PLoS ONE.
5:e101472010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He XQ, Dong YJ, Wu CW, et al: MicroRNA-218
inhibits cell cycle progression and promotes apoptosis in colon
cancer by downregulating BMI1 polycomb ring finger oncogene. Mol
Med. 18:1491–1498. 2012.PubMed/NCBI
|
